Edward Tobinick, M.D. Selected Publications

Selected Scientific Publications by Edward Tobinick, M.D.

  1. E. Tobinick, D. Ucci, K. Bermudo, and S. Asseraf, Perispinal etanercept stroke trial design: PESTO and beyond. Expert Opinion on Biological Therapy, 2024. 24(10): p. 1095-1108.
  2. E. Tobinick, R. N. Spengler, T. A. Ignatowski, M. Wassel, et al., Rapid improvement in severe long COVID following perispinal etanercept. Current Medical Research and Opinion, 2022. 38(12): p. 2013-2020.
  3. E. Tobinick, Immediate Resolution of Hemispatial Neglect and Central Post-Stroke Pain After Perispinal Etanercept: Case Report. Clinical Drug Investigation, 2020. 40(1): p. 93-97.
  4. Z. M. LaMacchia, R. N. Spengler, M. Jaffari, A. H. Abidi, E. Tobinick et al., Perispinal injection of a TNF blocker directed to the brain of rats alleviates the sensory and affective components of chronic constriction injury-induced neuropathic pain. Brain, Behavior and Immunity, 2019. 82: p. 93-105.
  5. E. Tobinick, Perispinal etanercept advances as a neurotherapeutic. Expert Review of Neurotherapeutics, 2018. 18(6): p. 453-455.
  6. E. L. Tobinick, Perispinal Delivery of CNS Drugs. CNS Drugs, 2016. 30(6): p. 469-80.
  7. E. Tobinick, H. Rodriguez-Romanacce, A. Levine, T. A. Ignatowski, et al., Immediate neurological recovery following perispinal etanercept years after brain injury. Clinical Drug Investigation, 2014. 34(5): p. 361-6.
  8. T. A. Ignatowski, R. N. Spengler, E. Tobinick, Authors’ reply to Whitlock: Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs, 2014. 28(12): p. 1207-13.
  9. E. Tobinick, T. A. Ignatowski, R. N. Spengler, K. M. Dhandapani, H. Folkersma, et al., Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs, 2014. 28(8): p. 679-97.
  10. E. Tobinick, Author’s reply to Page: “Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept”. CNS Drugs, 2013. 27(5): p. 399-402.
  11. E. Tobinick, N. M. Kim, G. Reyzin, H. Rodriguez-Romanacce, et al., Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs, 2012. 26(12): p. 1051-70.
  12. E. Tobinick, Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer’s disease. Current Alzheimer Research, 2012. 9(1): p. 99-109.
  13. E. Tobinick, Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs, 2011. 25(2): p. 145-55.
  14. E. Tobinick, Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Review of Neurotherapeutics, 2010. 10(6): p. 985-1002.
  15. E. L. Tobinick, K. Chen, and X. Chen, Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Research Notes, 2009. 2: p. 28.
  16. E. L. Tobinick, The value of drug repositioning in the current pharmaceutical market. Drug News and Perspectives, 2009. 22(2): p. 119-25.
  17. E. Tobinick, Perispinal etanercept for neuroinflammatory disorders. Drug Discovery Today, 2009. 14(3-4): p. 168-77.
  18. E. Tobinick, Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. CNS Drugs, 2009. 23(9): p. 713-25.
  19. E. L. Tobinick and H. Gross, Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. Journal of Neuroinflammation, 2008. 5: p. 2.
  20. E. L. Tobinick and H. Gross, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurology, 2008. 8: p. 27.
  21. E. L. Tobinick, A critique of intradiscal administration for treatment of radiculopathy. Anesthesiology, 2008. 108(2): p. 334; author reply 335.
  22. E. L. Tobinick, Re: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology, 2008. 70(14): p. 1222-3; author reply 1223.
  23. E. Tobinick, Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Medscape Journal of Medicine, 2008. 10(6): p. 135.
  24. E. Tobinick, Perispinal etanercept for treatment of Alzheimer’s disease. Curr Alzheimer Res, 2007. 4(5): p. 550-2.
  25. E. Tobinick and C. P. Vega, The cerebrospinal venous system: anatomy, physiology, and clinical implications. MedGenMed, 2006. 8(1): p. 53.
  26. E. Tobinick, H. Gross, A. Weinberger, and H. Cohen, TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. MedGenMed, 2006. 8(2): p. 25.
  27. E. Tobinick, Spinal delivery of p38: TNF-alpha inhibitors. PLoS Medicine, 2006. 3(11): p. e511.
  28. E. Tobinick and S. Davoodifar, Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin, 2004. 20(7): p. 1075-85.
  29. E. Tobinick, TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection. Curr Med Res Opin, 2004. 20(1): p. 39-40.
  30. E. L. Tobinick and S. Britschgi-Davoodifar, Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly, 2003. 133(11-12): p. 170-7.
  31. E. L. Tobinick, Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults. Clinical Therapeutics 2003. 25(4): p. 1211-8.
  32. E. L. Tobinick, Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther, 2003. 25(8): p. 2279-88.
  33. E. L. Tobinick, Basal cell carcinoma. American Family Physician, 1987. 36(3): p. 219-24.
  34. E. Tobinick, H. R. Schelbert, H. Henning, M. LeWinter, et al., Right ventricular ejection fraction in patients with acute anterior and inferior myocardial infarction assessed by radionuclide angiography. Circulation, 1978. 57(6): p. 1078-84.